The 131I-AC133.1 mAb was utilized to target CD133(+) colorectal CSCs, and analysis of the therapeutic effect (tumor VDT, median survival time, CD133 expression by flow cytometry, protein levels of cancer stem-like biomarkers, Ki67 and H&E staining of tumors) suggested that 131I-AC133.1 mAb could destroy CSCs and inhibit tumor development. The gene discussed is PROM1; the disease is neoplasm.